SS Innovations International (NASDAQ: SSII) is positioning itself as a significant contender in the emerging field of telerobotic surgery, according to a recent MedTech Dive report that examined the technology's global development and the regulatory and infrastructure questions surrounding remote surgery. The article highlighted SS Innovations alongside larger medical-device companies and emerging robotics developers, underscoring the company's growing relevance in a market that is moving from isolated demonstrations toward broader clinical and regulatory development.
At the center of this shift is the SSi Mantra system, which has been used in 195 robotic telesurgeries as of September 28, 2026, including cardiac procedures and long-distance operations. The company's installed base reached 244 SSi Mantra systems as of the same date, up 45% from the end of 2025, while cumulative procedures reached 14,503. These figures indicate not only adoption but also accumulating clinical experience, which is critical as remote surgery seeks wider acceptance. The technology has expanded into 12 countries, with recent cardiac-surgery programs launched in Colombia and Sri Lanka and a new program established at HCG Hospital in Ahmedabad.
In an interview with MedTech Dive, SS Innovations founder and CEO Dr. Sudhir Srivastava, a cardiac surgeon, noted that robotic surgery is inherently a form of teleoperation and that the central technical question is how much distance can be introduced without compromising responsiveness. This perspective frames the company's efforts as part of a broader industry conversation about the limits and possibilities of remote procedures. As detailed in the MedTech Dive report, which can be accessed at https://ibn.fm/4ZLvL, the development of telerobotic surgery raises important questions about latency, reliability, and regulatory frameworks that must be addressed before widespread adoption.
SS Innovations is currently pursuing U.S. FDA clearance and European Union CE marking as it seeks to expand the system into additional international markets. These regulatory milestones are essential for the company to compete in the world's largest healthcare markets and to validate its technology on a global scale. The pursuit of FDA clearance and CE marking signals that SS Innovations is preparing for a phase of growth that could significantly impact the surgical robotics landscape. For investors and industry observers, the company's progress in telerobotic surgery represents a potential inflection point, as remote procedures gain ground and the demand for accessible surgical care increases.
The implications of SS Innovations' advancements extend beyond the company itself. Telerobotic surgery could help address disparities in surgical care by enabling expert surgeons to operate on patients in remote or underserved areas. However, challenges related to infrastructure, such as reliable high-speed internet and secure data transmission, must be overcome. The MedTech Dive article examined these issues, and the full story is available through Read More. As SS Innovations continues to accumulate clinical experience and pursue regulatory approvals, its trajectory will be closely watched as a bellwether for the entire field.
For ongoing updates on SS Innovations, the company's newsroom can be found at https://ibn.fm/SSII. The original release is available on www.newmediawire.com.
